Research
Hormonal
Dual and triple incretin agonists (e.g., Tirzepatide, Retatrutide) achieve greater weight loss than single GLP-1 agonists by targeting multiple hormonal pathways.
Newer dual and triple hormone agonists offer even greater weight loss potential (up to 21%) than single-agonist GLP-1 drugs. They work by targeting multiple appetite and metabolism pathways simultaneously, making them highly effective for significant obesity.
StrongSupportsVERY_HIGH confidence
Emerging therapies, including triple agonists, amylin analogues, and myostatin-activin pathway inhibitors, target complementary hormonal and metabolic pathways and may further enhance weight loss and body composition outcomes.
Why this rating
Supported by Phase 3 trials (SURMOUNT, etc.).
Source
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Aya Bassatne et al. · Advances in Therapy · 2026
DOI 10.1007/s12325-026-03576-6
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →